Sionna Therapeutics, Inc.
NASDAQSionna Therapeutics heads into its August 11 earnings event with short sellers pulling back even as the stock's Phase 2a catalyst approaches — a split that puts the lending market and the clinical story in an unusual tension. Short interest, while still elevated at nearly 12% of the free float, has quietly retreated. Positions peaked above 5.55 million shares in mid-July and have…
SION cost to borrow surges to 2.17%, up 267% in one week as short sellers face rising borrow costs ahead of earnings.
Snapshot as of 11 Aug 2026
Sionna Therapeutics heads into its August 11 earnings event with short sellers pulling back even as the stock's Phase 2a catalyst approaches — a split that puts the lending market and the clinical story in an unusual…
Sionna Therapeutics faces earnings tomorrow with three signals pointing the same direction. Short sellers are building positions, options traders are piling into calls, and the borrow market is tightening — all at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SION — free to start on ORTEX.
Sign up for free →Open SION on ORTEX